描述 Ziritaxestat (GLPG1690), an autotaxin inhibitor, currently being evaluated in an exploratory phase 2 study in idiopathic pulmonary fibrosis patients. 激酶实验 Glutaminase Inhibition: Cell Free Assay: Assay plates are prepared containing 2 μL test compound in DMSO/well. The enzyme is diluted...
In a Phase 1 study in healthy human volunteers, GLPG1690 demonstrated favorable safety and tolerability, as well as a strong pharmacodynamic signal implying target engagement. 关键字: GLPG-1690 | ziritaxestat | CAS 1628260-79-6 公司简介 Wuhan Sun-shine Bio-technology Corporation Limited (Shang...
原文来源: https://sclerodermanews.com/2019/12/09/galapagos-phase-2a-trial-testing-glpg1690-diffuse-cutaneous-scleroderma-completes-enrollment/ 翻译/程晓波 校对/郑嫒 排版/瑶瑶 - END -